SK7592002A3 - Method and compositions for treating pulmonary diseases - Google Patents

Method and compositions for treating pulmonary diseases Download PDF

Info

Publication number: SK7592002A3
Authority: SK; Slovakia
Prior art keywords: pde4; rolipram; compounds; asthma; dose
Prior art date: 1999-11-02

Application number

SK759-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Peter N Goodfellow

Richard Nieman

Theodore J Torphy

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-02

Filing date

2000-11-01

Publication date

2002-11-06

2000-11-01 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2002-11-06 Publication of SK7592002A3 publication Critical patent/SK7592002A3/sk

Links

208000019693 Lung disease Diseases 0.000 title claims abstract description 13
239000000203 mixture Substances 0.000 title description 11
238000000034 method Methods 0.000 title description 7
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 19
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 19
239000003246 corticosteroid Substances 0.000 claims abstract description 12
230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims description 23
238000011282 treatment Methods 0.000 claims description 19
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 8
229960004436 budesonide Drugs 0.000 claims description 7
229940092705 beclomethasone Drugs 0.000 claims description 6
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 6
150000003431 steroids Chemical class 0.000 claims description 6
229960002744 mometasone furoate Drugs 0.000 claims description 5
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
229960002117 triamcinolone acetonide Drugs 0.000 claims description 4
229960003957 dexamethasone Drugs 0.000 claims description 3
229960000676 flunisolide Drugs 0.000 claims description 3
229960002714 fluticasone Drugs 0.000 claims description 3
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 3
230000002035 prolonged effect Effects 0.000 claims description 3
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 3
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
208000006673 asthma Diseases 0.000 abstract description 24
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 30
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 27
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 26
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 26
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 26
230000000694 effects Effects 0.000 description 24
230000027455 binding Effects 0.000 description 20
229950005741 rolipram Drugs 0.000 description 20
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 15
229940079593 drug Drugs 0.000 description 15
230000003197 catalytic effect Effects 0.000 description 10
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
-1 cyclopentyloxy-4-methoxyphenyl Chemical group 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
108010044467 Isoenzymes Proteins 0.000 description 5
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 5
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
238000009472 formulation Methods 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 4
102000030621 adenylate cyclase Human genes 0.000 description 4
108060000200 adenylate cyclase Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
229960005127 montelukast Drugs 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000005091 airway smooth muscle Anatomy 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
238000012790 confirmation Methods 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
238000011161 development Methods 0.000 description 3
230000006872 improvement Effects 0.000 description 3
229940125369 inhaled corticosteroids Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
206010003557 Asthma exercise induced Diseases 0.000 description 2
208000004657 Exercise-Induced Asthma Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013566 allergen Substances 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
229950000210 beclometasone dipropionate Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229940124748 beta 2 agonist Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
229940095074 cyclic amp Drugs 0.000 description 2
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
238000013461 design Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 2
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960004584 methylprednisolone Drugs 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000004044 response Effects 0.000 description 2
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000001262 western blot Methods 0.000 description 2
XTNYQMSCYWBFJX-KRWDZBQOSA-N (4r)-1-[(4-bromophenyl)methyl]-4-(2-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound C([C@H](CC1=O)C2=CC=C(C=C2OC2CCCC2)OC)N1CC1=CC=C(Br)C=C1 XTNYQMSCYWBFJX-KRWDZBQOSA-N 0.000 description 1
PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
MRHCSNNEUHXNIC-UHFFFAOYSA-N 9-benzylpurin-6-amine Chemical class C1=NC=2C(N)=NC=NC=2N1CC1=CC=CC=C1 MRHCSNNEUHXNIC-UHFFFAOYSA-N 0.000 description 1
AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000037874 Asthma exacerbation Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
206010018762 Grunting Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
CDKNUFNIFGPFSF-AYVLZSQQSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O CDKNUFNIFGPFSF-AYVLZSQQSA-N 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229960004495 beclometasone Drugs 0.000 description 1
229940098032 beconase Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000005528 benzodioxoles Chemical class 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000008512 biological response Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
229960003728 ciclesonide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
229950004687 denbufylline Drugs 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000003912 environmental pollution Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000013265 extended release Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229940033835 flonase Drugs 0.000 description 1
XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000010440 gypsum Substances 0.000 description 1
229910052602 gypsum Inorganic materials 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
FXXQDYPNDZFBMV-UHFFFAOYSA-N methyl 5-cyano-5-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxocyclohexane-1-carboxylate Chemical compound C1CC(=O)C(C(=O)OC)CC1(C#N)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 FXXQDYPNDZFBMV-UHFFFAOYSA-N 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
229940002297 nasacort Drugs 0.000 description 1
229940100656 nasal solution Drugs 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
229940003691 nasonex Drugs 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940124624 oral corticosteroid Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940071462 oralone Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
229940072266 pulmicort Drugs 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
208000024981 pyrosis Diseases 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
229950004432 rofleponide Drugs 0.000 description 1
229960002586 roflumilast Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK759-2002A 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases SK7592002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16315899P	1999-11-02	1999-11-02
PCT/US2000/030113 WO2001032127A2 (fr)	1999-11-02	2000-11-01	Procede et compositions pour traiter des maladies respiratoires

Publications (1)

Publication Number	Publication Date
SK7592002A3 true SK7592002A3 (en)	2002-11-06

Family

ID=22588737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK759-2002A SK7592002A3 (en)	1999-11-02	2000-11-01	Method and compositions for treating pulmonary diseases

Country Status (29)

Country	Link
EP (1)	EP1225866A4 (fr)
JP (1)	JP2003513028A (fr)
KR (1)	KR20020057988A (fr)
CN (1)	CN1387404A (fr)
AP (1)	AP2002002496A0 (fr)
AR (1)	AR029189A1 (fr)
AU (1)	AU1357501A (fr)
BG (1)	BG106748A (fr)
BR (1)	BR0015270A (fr)
CA (1)	CA2388333A1 (fr)
CO (1)	CO5261512A1 (fr)
CZ (1)	CZ20021512A3 (fr)
DZ (1)	DZ3225A1 (fr)
EA (1)	EA200200518A1 (fr)
EC (1)	ECSP003747A (fr)
HK (1)	HK1049107A1 (fr)
HU (1)	HUP0203152A3 (fr)
IL (1)	IL149367A0 (fr)
MA (1)	MA26841A1 (fr)
MX (1)	MXPA02004350A (fr)
NO (1)	NO20022057L (fr)
OA (1)	OA12076A (fr)
PE (1)	PE20011005A1 (fr)
PL (1)	PL355261A1 (fr)
SK (1)	SK7592002A3 (fr)
TR (1)	TR200201211T2 (fr)
TW (1)	TWI242431B (fr)
WO (1)	WO2001032127A2 (fr)
ZA (1)	ZA200203435B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002337105B2 (en) *	2001-09-19	2008-03-20	Takeda Gmbh	Combination of a NSAID and a PDE-4 inhibitor
US20040259863A1 (en) *	2001-10-31	2004-12-23	Hans-Michael Eggenweiler	Type 4 phosphodiesterase inhibitors and uses thereof
UA82323C2 (uk) *	2002-08-09	2008-04-10	Меда Фарма Гмбх & Ко. Кг	Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
TW200410923A (en) *	2002-10-17	2004-07-01	Ono Pharmaceutical Co	Therapeutic agent for chronic obstructive pulmonary disease
EP1616569A1 (fr) *	2003-03-31	2006-01-18	Kyowa Hakko Kogyo Co., Ltd.	Composition therapeutique
US20050026883A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JPWO2006041121A1 (ja) *	2004-10-13	2008-05-15	協和醗酵工業株式会社	慢性皮膚疾患の治療および／または予防剤
US20090054382A1 (en) *	2005-10-19	2009-02-26	Abhijit Ray	Compositions of phosphodiesterase type iv inhibitors
CN102665807A (zh)	2010-01-05	2012-09-12	微剂量治疗技术公司	吸入设备和方法
WO2015063669A1 (fr)	2013-10-30	2015-05-07	Wockhardt Limited	Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0710109B1 (fr) *	1993-06-18	2004-09-15	Smithkline Beecham Corporation	Méthode d'identification d'un inhibiteur de la PDE IV
DE4332041C2 (de) *	1993-09-21	1997-12-11	Rentschler Arzneimittel	Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
SE9801368D0 (sv) *	1998-04-20	1998-04-20	Astra Ab	New use

2000
- 2000-10-31 EC EC2000003747A patent/ECSP003747A/es unknown
- 2000-10-31 AR ARP000105742A patent/AR029189A1/es not_active Application Discontinuation
- 2000-11-01 MX MXPA02004350A patent/MXPA02004350A/es unknown
- 2000-11-01 CA CA002388333A patent/CA2388333A1/fr not_active Abandoned
- 2000-11-01 AP APAP/P/2002/002496A patent/AP2002002496A0/en unknown
- 2000-11-01 AU AU13575/01A patent/AU1357501A/en not_active Abandoned
- 2000-11-01 SK SK759-2002A patent/SK7592002A3/sk unknown
- 2000-11-01 PL PL00355261A patent/PL355261A1/xx not_active Application Discontinuation
- 2000-11-01 HK HK02109234.5A patent/HK1049107A1/zh unknown
- 2000-11-01 EP EP00975533A patent/EP1225866A4/fr not_active Withdrawn
- 2000-11-01 EA EA200200518A patent/EA200200518A1/ru unknown
- 2000-11-01 BR BR0015270-6A patent/BR0015270A/pt not_active IP Right Cessation
- 2000-11-01 KR KR1020027005609A patent/KR20020057988A/ko not_active Ceased
- 2000-11-01 HU HU0203152A patent/HUP0203152A3/hu unknown
- 2000-11-01 TR TR2002/01211T patent/TR200201211T2/xx unknown
- 2000-11-01 DZ DZ003225A patent/DZ3225A1/fr active
- 2000-11-01 CZ CZ20021512A patent/CZ20021512A3/cs unknown
- 2000-11-01 IL IL14936700A patent/IL149367A0/xx unknown
- 2000-11-01 CN CN00815265A patent/CN1387404A/zh active Pending
- 2000-11-01 WO PCT/US2000/030113 patent/WO2001032127A2/fr not_active Ceased
- 2000-11-01 OA OA1200200124A patent/OA12076A/en unknown
- 2000-11-01 JP JP2001534335A patent/JP2003513028A/ja active Pending
- 2000-11-02 PE PE2000001168A patent/PE20011005A1/es not_active Application Discontinuation
- 2000-11-02 CO CO00083427A patent/CO5261512A1/es not_active Application Discontinuation
- 2000-11-22 TW TW089123039A patent/TWI242431B/zh not_active IP Right Cessation
2002
- 2002-04-30 ZA ZA200203435A patent/ZA200203435B/xx unknown
- 2002-04-30 NO NO20022057A patent/NO20022057L/no not_active Application Discontinuation
- 2002-05-02 MA MA26621A patent/MA26841A1/fr unknown
- 2002-05-29 BG BG106748A patent/BG106748A/xx unknown

Also Published As

Publication number	Publication date
AU1357501A (en)	2001-05-14
EA200200518A1 (ru)	2002-10-31
TWI242431B (en)	2005-11-01
EP1225866A4 (fr)	2004-04-21
AR029189A1 (es)	2003-06-18
KR20020057988A (ko)	2002-07-12
PE20011005A1 (es)	2001-09-28
BG106748A (en)	2003-02-28
HUP0203152A2 (hu)	2003-01-28
BR0015270A (pt)	2002-06-18
ZA200203435B (en)	2003-06-25
MXPA02004350A (es)	2002-11-07
ECSP003747A (es)	2002-05-23
CA2388333A1 (fr)	2001-05-10
NO20022057D0 (no)	2002-04-30
OA12076A (en)	2006-05-04
WO2001032127A2 (fr)	2001-05-10
DZ3225A1 (fr)	2001-05-10
CZ20021512A3 (cs)	2003-04-16
CN1387404A (zh)	2002-12-25
TR200201211T2 (tr)	2002-08-21
HUP0203152A3 (en)	2004-06-28
MA26841A1 (fr)	2004-12-20
AP2002002496A0 (en)	2002-06-30
EP1225866A2 (fr)	2002-07-31
PL355261A1 (en)	2004-04-05
CO5261512A1 (es)	2003-03-31
WO2001032127A3 (fr)	2001-12-06
NO20022057L (no)	2002-06-27
HK1049107A1 (zh)	2003-05-02
JP2003513028A (ja)	2003-04-08
IL149367A0 (en)	2002-11-10

Publication	Publication Date	Title
US20050070514A1 (en)	2005-03-31	Therapies for treating respiratory diseases
EP2156840B1 (fr)	2011-08-10	Utilisation du furoate de mometasone pour le traitement des affections pulmonaires et des voies respiratoires
CZ2001692A3 (cs)	2002-02-13	Farmaceutický prostředek pro léčbu plicní nemoci a způsob výroby tohoto prostředku
KR20050104367A (ko)	2005-11-02	타 활성제와 결합하여 장기 효능을 지속하는 베타2-동근으로 구성되는 약물
US20040176419A1 (en)	2004-09-09	Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
SK7592002A3 (en)	2002-11-06	Method and compositions for treating pulmonary diseases
US20040219137A1 (en)	2004-11-04	Method for reducing exacerbations associated with COPD
AU2003292120B2 (en)	2010-01-21	New synergistic combination comprising roflumilast and formoterol
JP2004505039A (ja)	2004-02-19	Ｃｏｐｄに付随する増悪の減少方法
US20040214805A1 (en)	2004-10-28	Method and compositions for treating pulmonary diseases
TWI494108B (zh)	2015-08-01	糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
AU2004205324A1 (en)	2004-09-23	Method and compositions for treating pulmonary diseases
EP1261331A1 (fr)	2002-12-04	Procede et compositions permettant de traiter les maladies fibrosantes
US20030018071A1 (en)	2003-01-23	Method and compositions for treating fibrotic diseases
EA009990B1 (ru)	2008-04-28	Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
CN115697346A (zh)	2023-02-03	适应障碍的治疗
HK1135331B (en)	2011-12-30	Use of mometasone furoate for treating airway passage and lung diseases